Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Join us for exciting new data and high quality education
Stay updated with the most recent research in mCRC and submit your questions to the experts
Register now for the premier congress on early phase clinical trials in oncology, onsite in Paris and online on 7-9 March 2022!
Register now for ESMO Sarcoma & GIST 2022, onsite in Milan, and online on 31 January – 2 February. Benefit from the best available rates!
Your lung cancer research will get the best visibility
The latest in head and neck cancer
The ESMO-MCBS is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Reserved for registered users
Access the recording and presentation slides for this real-world case discussion with the experts developing and implementing the ESMO Guidelines
Discover the latest data for management of aHCC, with encouraging results in NSCLC
On the ESMO Perspectives, Elena Garralda discusses the latest achievements in precision oncology
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
ESMO would like to thank Dr Gustavo A. Lopez for his help in validation of translation in Spanish language
Efficacy was evaluated in KEYNOTE-716 study
In a prespecified RxPONDER analysis, postmenopausal women with 1 to 3 positive axillary lymph nodes and a recurrence score of 0 to 25 were able to safely forgo adjuvant chemotherapy for breast cancer
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
Efficacy was evaluated in KEYNOTE-716 study
In a prespecified RxPONDER analysis, postmenopausal women with 1 to 3 positive axillary lymph nodes and a recurrence score of 0 to 25 were able to safely forgo adjuvant chemotherapy for breast cancer
Retrieval of previously unreported data of PD-L1 subgroups from pivotal phase III randomised studies
When classified into gain-of-function and non–gain-of-function, p53 mutations could stratify the prognosis of right-sided versus left-sided metastatic colorectal cancer
Efficacy was evaluated in a single-arm cohort of PLEIADES study
The results from an open-label phase II study in patients with carcinoma of unknown primary
The results from a head-to-head comparison of two different neurokinin-1 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Longest median overall survival in a phase III melanoma study reported to date and the first report of melanoma-specific survival
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant PEComa
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
Results of the ESMO Women for Oncology monitoring and authorship studies
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial
The addition of immunotherapy to standard first-line treatment extends survival by eight months
ESMO President will act as an Advisor
ESMO delivered an official statement at the Special Session of the World Health Assembly to strengthen pandemic prevention, preparedness and response
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
The ESMO Immuno-Oncology Congress will be an online-only meeting
The collaborative study shows significant gaps in low- and middle-income countries
ESMO has announced today that the 2021 ESMO Award for Immuno-oncology is presented to Hervé Fridman
ESMO has announced today the winners of the 2021 Society Awards.
Record Impact Factor increases for ESMO journals
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Italy
South Africa
Belgium
France
Mexico
Mexico
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
